As the U.S. stock market inches higher, with major indices nearing record highs, investors are closely watching key developments such as Nvidia's earnings report and shifts in Federal Reserve policy. Amid these broader market dynamics, penny stocks—often representing smaller or newer companies—remain a relevant area of interest for those seeking growth opportunities beyond the well-known names. Despite being considered a niche investment category today, penny stocks can offer significant potential when backed by strong financial health and fundamentals.
Top 10 Penny Stocks In The United States
| Name | Share Price | Market Cap | Rewards & Risks |
| Dingdong (Cayman) (DDL) | $2.19 | $484.33M | ✅ 5 ⚠️ 0 View Analysis > |
| ATRenew (RERE) | $4.62 | $1B | ✅ 3 ⚠️ 0 View Analysis > |
| Waterdrop (WDH) | $1.82 | $647.38M | ✅ 4 ⚠️ 0 View Analysis > |
| CuriosityStream (CURI) | $4.44 | $257.21M | ✅ 4 ⚠️ 2 View Analysis > |
| WM Technology (MAPS) | $1.17 | $196.67M | ✅ 4 ⚠️ 2 View Analysis > |
| Performance Shipping (PSHG) | $1.89 | $24.93M | ✅ 4 ⚠️ 2 View Analysis > |
| Table Trac (TBTC) | $4.85 | $21.11M | ✅ 2 ⚠️ 2 View Analysis > |
| BAB (BABB) | $0.93 | $6.81M | ✅ 2 ⚠️ 3 View Analysis > |
| Lifetime Brands (LCUT) | $3.90 | $90.63M | ✅ 3 ⚠️ 3 View Analysis > |
| Resources Connection (RGP) | $4.85 | $161.7M | ✅ 3 ⚠️ 1 View Analysis > |
Click here to see the full list of 385 stocks from our US Penny Stocks screener.
Below we spotlight a couple of our favorites from our exclusive screener.
CuriosityStream (CURI)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: CuriosityStream Inc. is a media and entertainment company that offers factual content across various channels, with a market cap of $257.21 million.
Operations: The company generates $60.84 million in revenue from its media and entertainment offerings.
Market Cap: $257.21M
CuriosityStream Inc. has shown strategic growth through partnerships and content expansion, notably with a multi-tier distribution agreement with DIRECTV and the launch of its service as an add-on subscription on Prime Video in Australia and New Zealand. Despite being unprofitable, the company reported US$19.01 million in sales for Q2 2025, up from US$12.4 million a year ago, indicating revenue growth potential. The recent follow-on equity offering raised US$24.5 million to support further expansion efforts. With sufficient cash runway exceeding three years and no substantial insider selling recently, CuriosityStream is positioned for continued development within the media landscape.
- Navigate through the intricacies of CuriosityStream with our comprehensive balance sheet health report here.
- Understand CuriosityStream's earnings outlook by examining our growth report.
Caribou Biosciences (CRBU)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Caribou Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing genome-edited allogeneic cell therapies for hematologic malignancies and autoimmune diseases, with a market cap of approximately $175.07 million.
Operations: Caribou Biosciences generates revenue primarily from its pipeline focused on allogeneic CAR-T and CAR-NK cell therapies, amounting to $9.12 million.
Market Cap: $175.07M
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, is navigating the penny stock landscape with a market cap of US$175.07 million and revenue of US$9.12 million from its CAR-T and CAR-NK cell therapy pipeline. Despite being unprofitable with increasing losses—US$54.1 million for Q2 2025—the company maintains a strong financial position with short-term assets (US$192.5M) covering liabilities and no debt burden. Management's experience is complemented by sufficient cash runway exceeding one year, although recent volatility remains high due to strategic moves like the approved reverse stock split aimed at enhancing share value stability.
- Click here and access our complete financial health analysis report to understand the dynamics of Caribou Biosciences.
- Review our growth performance report to gain insights into Caribou Biosciences' future.
Kaltura (KLTR)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Kaltura, Inc. offers a range of software-as-a-service (SaaS) and platform-as-a-service (PaaS) products globally, with a market cap of approximately $242.55 million.
Operations: Kaltura generates revenue through two primary segments: Media & Telecom, contributing $48.39 million, and Enterprise, Education and Technology, which accounts for $132.96 million.
Market Cap: $242.55M
Kaltura, Inc., with a market cap of US$242.55 million, operates in the SaaS and PaaS sectors, generating revenue from Media & Telecom (US$48.39M) and Enterprise segments (US$132.96M). Despite being unprofitable, Kaltura has improved its financial standing by reducing losses at 23.7% annually over five years and maintaining a positive cash flow with a runway exceeding three years. Recent earnings showed reduced net loss for Q2 2025 compared to the previous year, while an extended partnership with Vodafone underscores potential growth in Cloud TV services, enhancing user engagement through AI-driven innovations without significant insider selling concerns recently noted.
- Click to explore a detailed breakdown of our findings in Kaltura's financial health report.
- Evaluate Kaltura's prospects by accessing our earnings growth report.
Where To Now?
- Gain an insight into the universe of 385 US Penny Stocks by clicking here.
- Curious About Other Options? Uncover 13 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Kaltura might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com